Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Protein’eXpert changes name to PX’Therapeutics
The new name builds on an already strong European position as a contract research and manufacturing organization specialized in the development of recombinant biotherapeutics, the company said. Tristan
The new name builds on an already strong European position as a contract research and manufacturing organization specialized in the development of recombinant biotherapeutics, the company said. Tristan
Mr Lim and Mr Wan are both independent directors and will serve on the audit committee, the compensation committee, and the corporate governance and nominating committees. Mr Wan
The restructuring program, which includes projects in all four business segments and at corporate, will result in the company incurring pre-tax charges of approximately $200 million beginning in
Doctors who specialize in treating cancer choose to have Biologics dispense prescriptions for their patients because of its fast turn around times, exceptional service and clinical oncology expertise,
These shares were priced at the closing price of $16.44 per share as of September 26, 2008, plus $0.0625 per share, and warrants to purchase an additional 757,461
The launch of Aigisrx implantable cardioverter defibrillator (ICD) is said to extend TyRx’s Aigisrx cardiac rhythm management device (CRMD) platform to the implantable cardioverter defibrillator market. The Aigisrx
The results included sub-analyses conducted to understand how EnteroMedics’s Vbloc vagal blocking therapy affects two co-morbidities frequently associated with obesity: type 2 diabetes and hypertension. Approximately six patients
Using an intelligent traffic light system, Biotronik Home Monitoring quickly and easily identifies patients with the most clinically relevant events to streamline clinic workflow and improve patient care,
The agreement provides Nomad access to Icon’s proprietary technology platforms, including its transient expression technology magnICON, for manufacturing biomaterials and selected biosimilar pharmaceutical proteins in green plants. The
The abbreviated new drug application (ANDA) was submitted to the FDA on August 5, 2008. This is said to be the first application filed by Scolr Pharma with